Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 8Withdrawn 2Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Hodgkin Disease 8Mycosis Fungoides 3Lymphoma, T-Cell, Peripheral 3Recurrence 2Lymphoma, T-Cell, Cutaneous 2Sezary Syndrome 1Mesothelioma, Malignant 1Lymphomatoid Papulosis 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Follicular 1Lymphoma 1Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 1Leukemia, Large Granular Lymphocytic 1

Interventions

Cyclophosphamide 8Biopsy 8Specimen Handling 7Magnetic Resonance Spectroscopy 6fludarabine 5ruxolitinib 4Vincristine 4X-Rays 3Whole-Body Irradiation 3Peripheral Blood Stem Cell Transplantation 3Cytarabine 310-propargyl-10-deazaaminopterin 3sodium-iodide symporter 2pembrolizumab 2duvelisib 2cemiplimab 2Prednisone 2Photons 2Methotrexate 2Immunoglobulin G 2Hydrocortisone 2Granulocyte Colony-Stimulating Factor 2Filgrastim 2Etoposide 2Doxorubicin 2Disulfides 2Dexamethasone 2Calcium Dobesilate 2Azacitidine 2venetoclax 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Lymphoma, T-Cell × Brentuximab Vedotin × Clear all
NCT05313243 2025-03-20

Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma

Yale University

Phase 2 Recruiting
32 enrolled
DermatologicLymphoid

Recurrence, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡